← Back to Search

Long-term Follow-Up of Participants exposed to SKG0106 Dose level 3 for Age-Related Macular Degeneration

N/A
Recruiting
Research Sponsored by Skyline Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years post study drug injection
Awards & highlights
No Placebo-Only Group

Summary

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years post study drug injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years post study drug injection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Mean change in best corrected visual acuity (BCVA) at each visit from baseline
Mean change in macular central subfield thickness (CST) at each visit from baseline
Mean change in patient-reported outcome (VFQ-25) scale scores at each visit from baseline

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Long-term Follow-Up of Participants exposed to SKG0106 Dose level 3Experimental Treatment1 Intervention
No investigational product will be administered in this study.
Group II: Long-term Follow-Up of Participants exposed to SKG0106 Dose level 2Experimental Treatment1 Intervention
No investigational product will be administered in this study.
Group III: Long-term Follow-Up of Participants exposed to SKG0106 Dose level 1Experimental Treatment1 Intervention
No investigational product will be administered in this study.

Find a Location

Who is running the clinical trial?

Skyline TherapeuticsLead Sponsor
~55 spots leftby Mar 2031
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top